New arrhythmia technologies

New arrhythmia technologies , New arrhythmia technologies , کتابخانه دیجیتالی دانشگاه علوم پزشکی و خدمات درمانی شهید بهشتی

[1]  M. Brodsky,et al.  Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study , 2000, Circulation.

[2]  S. Connolly,et al.  Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. , 2001, The American journal of cardiology.

[3]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[4]  D. Juurlink,et al.  Drugs and the QT interval - caveat doctor. , 2004, The New England journal of medicine.

[5]  A. Garfinkel,et al.  Novel approaches to identifying antiarrhythmic drugs. , 2003, Trends in cardiovascular medicine.

[6]  M. Niebauer,et al.  Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. , 2003, The American journal of cardiology.

[7]  A. Camm,et al.  The azimilide post-infarct survival evaluation (ALIVE) trial. , 1998, The American journal of cardiology.

[8]  The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. , 2004, Journal of the American College of Cardiology.

[9]  G. Billman.  RSD-1235. Cardiome. , 2003, Current opinion in investigational drugs.

[10]  P. Kowey,et al.  Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. , 1995, Circulation.

[11]  G. Naccarelli,et al.  Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. , 2003, The American journal of cardiology.

[12]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[13]  K. Stangl,et al.  Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. , 2000, Journal of the American College of Cardiology.

[14]  G. Naccarelli,et al.  A Review of Clinical Trials Assessing the Efficacy and Safety of Newer Antiarrhythmic Drugs in Atrial Fibrillation , 2003, Journal of Interventional Cardiac Electrophysiology.

[15]  P. Kowey,et al.  Dose-Ranging Study of Intravenous Amiodarone in Patients With Life-Threatening Ventricular Tachyarrhythmias , 1995 .

[16]  E. Bernal,et al.  Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study , 2002, Circulation.

[17]  M. Santini,et al.  New Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation , 2002, Pacing and clinical electrophysiology : PACE.

[18]  Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study ☆ , 2002 .

[19]  I Kodama,et al.  Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. , 1999, European journal of pharmacology.

[20]  Kenneth Egstrup,et al.  Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial , 2000, The Lancet.

[21]  R. Page,et al.  Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. , 2003, The American journal of cardiology.

[22]  A. Camm,et al.  Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? , 2004, Heart rhythm.

[23]  I. V. Van Gelder,et al.  Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[24]  J. Carlquist,et al.  Cardiovascular Pharmacogenomics: Current Status, Future Prospects , 2003, Journal of cardiovascular pharmacology and therapeutics.

[25]  S. Kathöfer,et al.  Antiarrhythmic drug carvedilol inhibits HERG potassium channels. , 2001, Cardiovascular research.

[26]  G. Lip,et al.  Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). , 2002, The American journal of cardiology.

[27]  H. N. Sabbah,et al.  Down-regulation of sodium current in chronic heart failure: effect of long-term therapy with carvedilol , 2002, Cellular and Molecular Life Sciences CMLS.

[28]  Silvia G Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.

[29]  L. Køber,et al.  Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy , 2001, Circulation.

[30]  P. Vardas,et al.  Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. , 2004, The American journal of cardiology.

[31]  E. Prystowsky,et al.  Clinical Experience with Dofetilide in the Treatment of Patients with Atrial Fibrillation , 2003, Journal of cardiovascular electrophysiology.

[32]  G. Lip,et al.  Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility , 2004, Expert opinion on investigational drugs.

[33]  D. Roden.  Antiarrhythmic drugs: past, present, and future. , 2004, Heart rhythm.

[34]  S. Hohnloser,et al.  Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. , 2004, Journal of the American College of Cardiology.

[35]  P. Mátyus,et al.  Novel antiarrhythmic compounds with combined class IB and class III mode of action. , 2004, Current medicinal chemistry.

[36]  Bramahn . Singh,et al.  Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone. , 1999, Circulation.

[37]  V. Fuster,et al.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.

[38]  G. Paxinos,et al.  Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. , 2003, The American journal of cardiology.

[39]  P. Kowey,et al.  Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. , 1995, Circulation.

[40]  J. Cleland,et al.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? , 2003, Journal of the American College of Cardiology.

[41]  P. Kowey,et al.  Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. , 1995, Circulation.